TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Multiple myeloma (MM) is an incurable blood cancer with limited treatment options for high-risk patients.
• Threonine and tyrosine kinase (TTK), also known as monopolar spindle 1 (MPS1), is crucial for cell division and linked to poor prognosis in various cancers.

Purpose of the Study:

• To investigate the role of TTK in MM and evaluate the efficacy of the TTK inhibitor OSU-13.
• To determine if TTK inhibition can serve as a therapeutic strategy for MM, especially in high-risk cases.

Main Methods:

• Assessed TTK expression levels and their correlation with patient survival and 1q21 genetic alterations in MM.
• Treated primary human MM cells and cell lines with OSU-13 in vitro, assessing effects on proliferation, viability, apoptosis, and DNA integrity.
• Evaluated OSU-13's anti-tumor activity in a mouse model of MM (NCI-H929 xenografts).

Main Results:

• Elevated TTK expression in MM correlated with 1q21 gain/amplification and reduced patient survival.
• OSU-13 effectively inhibited TTK, reduced MM cell proliferation and viability, and induced apoptosis.
• OSU-13 treatment led to DNA damage, aneuploidy, and decreased tumor growth in vivo.

Conclusions:

• TTK is a significant therapeutic target in multiple myeloma.
• Inhibiting TTK with OSU-13 demonstrates potent anti-myeloma activity, particularly in high-risk MM with 1q21 alterations.
• OSU-13 represents a promising novel therapeutic strategy for a subset of MM patients.